We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A U.S. district judge was wrong to bar Mylan Laboratories from continuing to sell the cancer drug paclitaxel pending an appeal of an earlier ruling that those sales infringed on NaPro Biotherapeutics’ formulation patents, a federal appeals court has ruled.
A consumer activist group is urging HHS Secretary Tommy Thompson to use a little-known federal law on the commercialization of government funded inventions to grant generic drugmakers patent licenses to make versions of Pfizer’s glaucoma drug Xalatan (latanoprost) and Abbott’s AIDS treatment Norvir (ritonavir).
GlaxoSmithKline (GSK) has agreed to pay $175 million to settle a class action lawsuit alleging the company violated antitrust laws in obtaining and enforcing its patent for the nonsteroidal anti-inflammatory drug Relafen (nabumetone) to the injury of drug wholesalers and other direct purchasers.
Mylan has been sued for patent infringement by Japanese drugmaker Eisai over its bid to market a version of Eisai’s gastrointestinal treatment Aciphex (rabeprazole sodium).
A federal district court on Feb. 4 vacated a preliminary injunction that GlaxoSmithKline (GSK) had sought against Eon Labs over its generic version of GSK’s antidepressant Wellbutrin SR (bupropion HCl) 100-mg tablets.
The FDA will appeal a recent district court ruling that overturned the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmith
The FDA yesterday said it will appeal a recent district court ruling that overturned the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmithKline’s depression drug Paxil (paroxetine HCl).
In a procedural move, a federal district court yesterday pulled a preliminary injunction that GlaxoSmithKline (GSK) had sought against Eon Labs over its generic version of GSK’s antidepressant Wellbutrin SR (bupropion HCl) 100-mg tablets.
Generic drug advocates in Europe and Canada say they face obstacles to increasing generic competition in their markets — something FDA Commissioner Mark McClellan has recently argued is necessary as part of a broader solution to lowering drug costs.
Japanese drugmaker Eisai has filed a patent infringement lawsuit against generic firm Mylan over its bid to market a version of Eisai’s gastrointestinal treatment Aciphex (rabeprazole sodium).